DE69324120D1 - HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS - Google Patents

HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS

Info

Publication number
DE69324120D1
DE69324120D1 DE69324120T DE69324120T DE69324120D1 DE 69324120 D1 DE69324120 D1 DE 69324120D1 DE 69324120 T DE69324120 T DE 69324120T DE 69324120 T DE69324120 T DE 69324120T DE 69324120 D1 DE69324120 D1 DE 69324120D1
Authority
DE
Germany
Prior art keywords
aids
protease inhibitors
hiv protease
treatment
chem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69324120T
Other languages
English (en)
Other versions
DE69324120T2 (de
Inventor
Louis Nickolaus Jungheim
Timothy Alan Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/134,329 external-priority patent/US5733906A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69324120D1 publication Critical patent/DE69324120D1/de
Publication of DE69324120T2 publication Critical patent/DE69324120T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60N-oxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69324120T 1992-12-22 1993-12-20 HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS Expired - Fee Related DE69324120T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99525692A 1992-12-22 1992-12-22
US08/134,329 US5733906A (en) 1993-10-12 1993-10-12 Inhibitors of HIV Protease useful for the treatment of Aids

Publications (2)

Publication Number Publication Date
DE69324120D1 true DE69324120D1 (de) 1999-04-29
DE69324120T2 DE69324120T2 (de) 1999-11-25

Family

ID=26832220

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69324120T Expired - Fee Related DE69324120T2 (de) 1992-12-22 1993-12-20 HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS

Country Status (21)

Country Link
US (1) US5905077A (de)
EP (1) EP0604185B1 (de)
JP (1) JPH06271534A (de)
KR (1) KR940014337A (de)
CN (1) CN1044117C (de)
AT (1) ATE178055T1 (de)
AU (1) AU667146B2 (de)
BR (1) BR9305162A (de)
CA (1) CA2112042A1 (de)
CZ (1) CZ281493A3 (de)
DE (1) DE69324120T2 (de)
ES (1) ES2132201T3 (de)
FI (1) FI935778A (de)
HU (1) HUT69693A (de)
IL (1) IL108092A (de)
MX (1) MX9308016A (de)
MY (1) MY131388A (de)
NO (1) NO934719L (de)
NZ (1) NZ250491A (de)
PL (1) PL301581A1 (de)
TW (1) TW262468B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
RU2126794C1 (ru) 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5461154A (en) * 1994-02-02 1995-10-24 Eli Lilly And Company Intermediate and process for making
TW472047B (en) * 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors
ES2116029T3 (es) * 1994-11-04 1998-07-01 Yamakawa Chemical Ind Procedimiento para preparar derivados de piperazina opticamente activos e intermedios para prepararlos.
CA2186483A1 (en) * 1995-02-03 1996-08-08 Akira Nishiyama Processes for producing .alpha.-halo ketones, .alpha.-halohydrins and epoxides
US5618937A (en) * 1995-03-15 1997-04-08 Merck & Co., Inc. Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide
US6222043B1 (en) 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
ES2318852T3 (es) * 1995-09-26 2009-05-01 Japan Tobacco Inc. Procedimiento para producir derivados de amida y compuestos intermedios.
US6133461A (en) * 1995-09-26 2000-10-17 Japan Tobacco Inc. Process for producing amide derivatives and intermediates therefor
EP0910564B1 (de) * 1995-11-28 2007-10-31 Cephalon, Inc. Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
CA2249747A1 (en) 1996-12-27 1998-07-09 Tsutomu Mimoto Novel tripeptide compounds and anti-aids drugs
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び/又は治療剤
DE69836315T2 (de) 1997-03-14 2007-05-31 Daiichi Pharmaceutical Co., Ltd. Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung
US6538006B1 (en) * 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
WO2000038618A2 (en) * 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
WO2001027091A1 (en) 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP1261610A2 (de) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino-carbocyclen und -heterocyclen als hemmer der a-beta-proteinbildung
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
CN1436175A (zh) * 2000-04-03 2003-08-13 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ-蛋白生产抑制剂的环状内酰胺
CN1434803A (zh) 2000-04-03 2003-08-06 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白质产生抑制剂的环内酰胺
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
JP2004500419A (ja) * 2000-04-11 2004-01-08 デュポン ファーマシューティカルズ カンパニー Aβタンパク質産生阻害剤としての置換ラクタム
WO2001087354A2 (en) * 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
MXPA02000862A (es) * 2000-06-01 2003-07-14 Bristol Myers Squibb Pharma Co Lactamas substituidas por succinatos ciclicos como inhibidores de la produccion de proteina abeta.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
JPWO2002064553A1 (ja) * 2001-02-14 2004-06-10 呉羽化学工業株式会社 ハロゲノアルコール誘導体の製造方法
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
GB0123467D0 (en) 2001-09-28 2001-11-21 Hoffmann La Roche Carbocyclic HIV Protease inhibitors
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
CN101508664B (zh) * 2009-02-25 2012-08-22 江阴希迪医药科技有限公司 N-苄氧羰基-3-氨基-1-氯-4-苯硫基-2-丁醇合成方法
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
PT2588450T (pt) * 2010-07-02 2017-08-03 Gilead Sciences Inc Derivados do ácido naft-2-ilacético para tratamento da sida
EP2699558B1 (de) 2011-04-21 2016-11-23 Gilead Sciences, Inc. Benzothiazol-verbindungen und ihre pharmazeutische verwendung
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2013159064A1 (en) 2012-04-20 2013-10-24 Gilead Sciences, Inc. Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
EP0361341A3 (de) * 1988-09-28 1991-07-03 Miles Inc. Therapeutika für AIDS auf der Basis von HIV-Protease-Inhibitoren
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
DK0813867T3 (da) 1990-11-19 2005-10-03 Monsanto Co Retrovirale proteaseinhibitorer
HUT60282A (en) * 1991-02-08 1992-08-28 Sankyo Co Process for producing new beta-amino-alpha-hydroxycarboxylic acid derivatives and pharmaceutical compositions comprising such compounds
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
WO1993013066A1 (en) 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines

Also Published As

Publication number Publication date
MX9308016A (es) 1994-08-31
TW262468B (de) 1995-11-11
EP0604185A1 (de) 1994-06-29
DE69324120T2 (de) 1999-11-25
KR940014337A (ko) 1994-07-18
EP0604185B1 (de) 1999-03-24
CN1094399A (zh) 1994-11-02
CN1044117C (zh) 1999-07-14
NO934719L (no) 1994-06-23
US5905077A (en) 1999-05-18
JPH06271534A (ja) 1994-09-27
FI935778A0 (fi) 1993-12-21
ATE178055T1 (de) 1999-04-15
BR9305162A (pt) 1994-11-01
CZ281493A3 (en) 1994-07-13
MY131388A (en) 2007-08-30
AU5252893A (en) 1994-07-07
CA2112042A1 (en) 1994-06-23
NO934719D0 (no) 1993-12-20
AU667146B2 (en) 1996-03-07
FI935778A (fi) 1994-06-23
IL108092A0 (en) 1994-04-12
PL301581A1 (en) 1994-06-27
ES2132201T3 (es) 1999-08-16
IL108092A (en) 1998-06-15
HUT69693A (en) 1995-09-28
NZ250491A (en) 1995-08-28

Similar Documents

Publication Publication Date Title
ATE178055T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
DE69334250D1 (de) Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
DK0604183T3 (da) HIV-protease-inhibitorer anvendelige i behandlingen af AIDS
DE69307674T2 (de) HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS
ATE113843T1 (de) Verwendung eines prolylendopeptidase-inhibitors zur behandlung von aids.
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
ATE137973T1 (de) Phospholipide zur behandlung der multiplen sklerose
RU93055680A (ru) Ингибиторы вич-протеазы, способ получения, их использование, композиция
RU93055681A (ru) Ингибиторы вич-протеазы, способ их получения, их использование в фармкомпозициях

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee